Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.

Trial Details

NCT ID
NCT02974647
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Ruxolitinib
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709

Key Eligibility Criteria

  • Pathologically confirmed T or NK cell lymphoma at the enrolling institution. For CTCL, patients with stage IB disease or greater are eligible.
  • Relapse or refractory disease after at least 1 systemic therapy except for T-PLL, LGL, or T-cell Lymphoproliferative diseases with JAK2 fusion.
  • Untreated patients may be allowed after discussion with P.I.
  • Measurable disease defined by:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →